Skip to content

Clinical study of gronethium bromide combined with dexmedetomidine in laparoscopic cholecystectomy

Clinical study of gronethium bromide combined with dexmedetomidine in laparoscopic cholecystectomy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081653
Enrollment
Unknown
Registered
2024-03-07
Start date
2024-03-08
Completion date
Unknown
Last updated
2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia for laparoscopic cholecystectomy

Interventions

Glycopyrronium bromide group :Glycopyrronium bromide was administered before induction
normal saline control group:Saline was given before induction

Sponsors

The First People's Hospital of JIngzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: (1) age range 18-64 years, no gender limitation, (2) ASA classification: I-II grade, no airway obstruction, (3) BMI: = 18-30kg/m2, (4) LC patients selected, (5) complete and accurate clinical data, (6) no obvious heart, lung, liver, kidney and other important organ dysfunction, (7) patients and their families fully understand the study process, willing to sign informed consent and strictly comply with the requirements of order.

Exclusion criteria

Exclusion criteria: Patients who were allergic to anticholinergic drugs and Dex and its components, (2) patients with severe organ dysfunction, ASA grade III or above, (3) patients with poor preoperative hypertension control (SBP > 160 mmHg or DBP > 100 mmHg) , (3) patients with severe organ dysfunction, (3) patients with severe preoperative hypertension control (SBP > 160 mmHg or DBP > 100 mmHg) , and (3) patients with severe postoperative hypertension (SBP > 160 mmHg or DBP > 100 mmHg) Patients with severe arrhythmias, unstable angina, unconsciousness or cognitive impairment, angle-closure glaucoma, myasthenia gravis, paralytic ileus, pyloric stenosis, and Benign prostatic hyperplasia; (7) pregnant or lactating patients; (8) participated in other drug clinical trials as subjects within the last 3 months; (9) did not participate in the trials and refused to give informed consent.

Design outcomes

Primary

MeasureTime frame
heart rate;

Secondary

MeasureTime frame
mean arterial pressure;The amount of gland secretion during extubation;Degree of postoperative pain;Postoperative Delirium;

Countries

China

Contacts

Public ContactXia Rui

The First People's Hospital of JIngzhou

879560350@qq.com+86 189 7216 1338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026